Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer

Chia Ming Yeh, Jacqueline Shay, Ting Chuan Zeng, Jian Liang Chou, Hui-ming Huang, Hung Cheng Lai, Michael W Y Chan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)2101-2107
Number of pages7
JournalInternational Journal of Oncology
Volume45
Issue number5
DOIs
StatePublished - Nov 1 2014

Fingerprint

Tumor Suppressor Genes
Epigenomics
Ovarian Neoplasms
Neoplasms
Histone Code
Cell Line
Circadian Clocks
CpG Islands
Cisplatin
Genes
Cause of Death
Polymerase Chain Reaction
Growth

Keywords

  • ARNTL
  • Circadian clock
  • Epigenetic modifications
  • Ovarian cancer
  • Tumor suppressor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. / Yeh, Chia Ming; Shay, Jacqueline; Zeng, Ting Chuan; Chou, Jian Liang; Huang, Hui-ming; Lai, Hung Cheng; Chan, Michael W Y.

In: International Journal of Oncology, Vol. 45, No. 5, 01.11.2014, p. 2101-2107.

Research output: Contribution to journalArticle

Yeh, Chia Ming ; Shay, Jacqueline ; Zeng, Ting Chuan ; Chou, Jian Liang ; Huang, Hui-ming ; Lai, Hung Cheng ; Chan, Michael W Y. / Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. In: International Journal of Oncology. 2014 ; Vol. 45, No. 5. pp. 2101-2107.
@article{a95390d580ec418aa33c544524c7f671,
title = "Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer",
abstract = "Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.",
keywords = "ARNTL, Circadian clock, Epigenetic modifications, Ovarian cancer, Tumor suppressor",
author = "Yeh, {Chia Ming} and Jacqueline Shay and Zeng, {Ting Chuan} and Chou, {Jian Liang} and Hui-ming Huang and Lai, {Hung Cheng} and Chan, {Michael W Y}",
year = "2014",
month = "11",
day = "1",
doi = "10.3892/ijo.2014.2627",
language = "English (US)",
volume = "45",
pages = "2101--2107",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer

AU - Yeh, Chia Ming

AU - Shay, Jacqueline

AU - Zeng, Ting Chuan

AU - Chou, Jian Liang

AU - Huang, Hui-ming

AU - Lai, Hung Cheng

AU - Chan, Michael W Y

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.

AB - Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.

KW - ARNTL

KW - Circadian clock

KW - Epigenetic modifications

KW - Ovarian cancer

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=84907197942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907197942&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2627

DO - 10.3892/ijo.2014.2627

M3 - Article

C2 - 25175925

AN - SCOPUS:84907197942

VL - 45

SP - 2101

EP - 2107

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -